[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-pancreatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-pancreatitis":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,47,0,25,[9,44,72,99,123,145,173,201,230,257,297,326,350,382,401,427,452,475,499,530,556,582,620,641,671],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100652181","the-biobank-integrating-longitudinal-ercp-within-a-prospective-chronic-pancreatitis-cohort-100652181",false,"NCT07770412","The Biobank Integrating Longitudinal ERCP Within a Prospective Chronic Pancreatitis Cohort","BILE-CP","Inclusion Criteria:\n\n* Age ≥ 18 years, with no sex restrictions.\n* Meets the diagnostic criteria for chronic pancreatitis, with a definitive diagnosis of chronic pancreatitis based on imaging, pathology, or pancreatic function tests;\n* Receiving medical care at the study center and willing to accept long-term follow-up management.\n* Able to cooperate with baseline data collection and scheduled follow-ups.\n* Provided written informed consent.\n\nExclusion Criteria:\n\n* Concomitant malignancies.\n* Concurrent severe systemic diseases with an expected life expectancy of \\\u003C 1 year.\n* History of major pancreatic resection or pancreaticoduodenectomy.\n* History of major gastrointestinal surgery.\n* Pregnant or lactating population.\n* Severe psychiatric disorders, cognitive dysfunction, or assessed by the investigator as having extremely poor compliance, rendering the participant unable to complete the scheduled follow-up plan.\n* Other relevant conditions deemed by the investigator as potentially affecting the study results or compromising participant safety.","ALL","18 Years",{"count":20,"type":21},1500,"ESTIMATED","OBSERVATIONAL","The Biobank Integrating Longitudinal ERCP within a Prospective Chronic Pancreatitis Cohort (BILE-CP) is a prospective longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The study plans to consecutively enroll 1,500 patients with chronic pancreatitis for long-term follow-up (scheduled every 6 months). This cohort encompasses patients across the entire disease course of chronic pancreatitis, with a particular focus on and in-depth tracking of a sub-cohort of patients undergoing ERCP treatments. During baseline and follow-up visits, researchers will collect multidimensional data from participants, including sociodemographics, diet and lifestyle, emotional status and sleep quality, clinical phenotypes and disease characteristics, ERCP intervention details, clinical laboratory and imaging examinations, continuous glucose monitoring (CGM), and traditional Chinese medicine indicators. Concurrently, multi-site biological samples will be collected, including but not limited to blood, feces, bile, saliva, tongue coating, and urine.",[25],"Chronic Pancreatitis",[27,28,29,30],"chronic pancreatitis","Endoscopic Retrograde Cholangiopancreatography","multi-omics","ERCP","NOT_YET_RECRUITING","2026-08-13",{"date":34,"type":35},"2026-08-18","ACTUAL",{"date":37,"type":21},"2026-08-15",{"date":39,"type":21},"2031-08-31",{"name":41,"class":42},"First People's Hospital of Hangzhou","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100651624","blood-biomarkers-and-gut-microbiota-for-pancreatic-cancer-risk-in-chronic-pancreatitis-100651624","NCT07762950","Blood Biomarkers and Gut Microbiota for Pancreatic Cancer Risk in Chronic Pancreatitis","Immune Repertoire Decoding Enables Dynamic Risk Stratification During Chronic Pancreatitis-to-Pancreatic Cancer Transition","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Able to understand the study procedures and provide written informed consent.\n* Healthy controls: participants without a known history of chronic pancreatitis or pancreatic cancer.\n* Chronic pancreatitis cohort: participants diagnosed with chronic pancreatitis according to clinical guidelines, based on clinical, imaging, and\u002For genetic information.\n* Pancreatic ductal adenocarcinoma cohort: participants with newly diagnosed pancreatic ductal adenocarcinoma based on clinical, imaging, and\u002For pathological evaluation.\n* Willing to provide blood samples and relevant clinical information.\n* For participants with chronic pancreatitis, willing to undergo longitudinal follow-up approximately every 6 to 12 months.\n\nExclusion Criteria:\n\n* Unable or unwilling to provide written informed consent.\n* Unable to provide required clinical information or biological samples.\n* Prior diagnosis of another active malignant tumor, except adequately treated non-melanoma skin cancer or carcinoma in situ, if considered not to affect study participation by the investigator.\n* Current severe acute infection or other serious medical condition that, in the investigator's judgment, may interfere with study participation or interpretation of immune-related analyses.\n* Use of systemic immunosuppressive therapy or immunotherapy within a period considered clinically relevant by the investigator.\n* Any condition that, in the investigator's judgment, makes the participant unsuitable for this study.",true,{"count":53,"type":21},800,"28 Months","The goal of this observational study is to learn more about pancreatic cancer risk in people with chronic pancreatitis. Researchers will study blood markers and gut microorganisms, which are bacteria and other microbes living in the intestine.\n\nResearchers will compare healthy participants, participants with chronic pancreatitis, and participants with newly diagnosed pancreatic cancer. The study will examine whether blood markers and gut microorganisms differ among these groups. It will also study how these features change over time and whether they may help identify people with chronic pancreatitis who are at higher risk of pancreatic cancer.\n\nParticipants will provide blood and stool samples. Researchers will also collect health information, laboratory test results, and abdominal scan results. Participants with chronic pancreatitis will be followed about every 6 to 12 months. Participants with pancreatic cancer will also be followed according to their routine medical care schedule. Researchers will collect information about their treatment, disease changes, test results, scans, and survival status.\n\nSome participants with chronic pancreatitis or pancreatic cancer may be asked to provide additional blood or stool samples. Their permission will be confirmed before each additional sample is collected. Refusing an additional sample will not affect their routine medical care or continued follow-up in the study.\n\nNo treatment will be assigned as part of this study. The findings may help improve future methods for assessing pancreatic cancer risk in people with chronic pancreatitis.",[25,57],"Pancreatic Cancer",[59,60,61,62,63],"Pancreatic Ductal Adenocarcinoma","Serum Biomarkers","Gut Microbiota","Microbial Translocation","Risk Stratification","2026-08-09",{"date":32,"type":35},{"date":67,"type":21},"2026-08-01",{"date":69,"type":21},"2028-12-31",{"name":71,"class":42},"Changhai Hospital",{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100651094","pirfenidone-as-treatment-of-chronic-pancreatitis-100651094","NCT07755813","Pirfenidone as Treatment of Chronic Pancreatitis","Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Chronic Pancreatitis.","PATCH","All subjects will be diagnosed with chronic pancreatitis (CP).\n\nInclusion Criteria:\n\n1. Patients 18 - 85 years of age\n2. Diagnosis of CP, based on at least one of the following on CT and\u002For MRI\u002FMRCP:\n\n   1. Pancreatic parenchymal and\u002For ductal calcification\n   2. Unequivocal CP on imaging (Tirkes et al3) (Cambridge grade 3 or grade 4)\n3. Average pain of \\>\u002F=4 (on a 0-10 scale) related to pancreatitis in the past three months \\[regardless of the use of pain medications (opioids or non-opioids)\\] and\u002For evidence of ongoing pancreatic inflammatory activity, with an inflammatory pancreatic flare occurring one or more times within the past six months \\[inflammatory pancreatic flare is defined as an exacerbation of pancreatic pain in combination with one or more of the following: 1) plasma amylase\u002Flipase levels elevated 2-folds or more than the upper limit of normal; 2) elevated plasma levels of CRP 2-fold or more than the upper normal level without suspicion of other sources such as infection; 3) signs of pancreatic inflammation on cross-sectional imaging\\]\n4. Ability to understand and the willingness to sign a written informed consent document and medical release\n5. Willing and able to comply with trial protocol and follow up\n\nExclusion Criteria\n\n1. Age \\\u003C 18 or \\> 85 years\n2. Pancreatic endotherapy and\u002For pancreatic surgery and\u002For celiac plexus block or neurolysis in last 3 months.\n3. Known hypersensitivity to Pirfenidone\n4. AST and\u002For ALT \\> times the upper normal limit\n5. Bilirubin higher than 1.5 times the upper normal limit\n6. Moderate to severe heart failure and\u002For coronary heart disease (New York Heart Association (NYHA) Functional Class III\u002FIV)\n7. On home oxygen or mechanical ventilation\n8. Clinically diagnosed cirrhosis\n9. Significant nausea and\u002For vomiting preventing administration of light diet\n10. Chronic diarrhea (\\>6 months, 3 or more stools\u002Fday, which in investigator's opinion is not due to pancreatic exocrine insufficiency)\n11. Active cancer (on chemotherapy, radiation or other treatment of cancer) or \\\u003C 3 years cancer free (non-melanoma skin cancers are not exclusion)\n12. Active hepatitis C\n13. Known history of hepatitis B\n14. Ongoing photosensitivity and rash\n15. Known live vaccines or therapeutic infectious agents within one month of potential enrollment\n16. Known pregnancy or lactation at the time of enrollment\n17. Women of childbearing potential who are not on oral or injectable contraceptives or not using an Intrauterine device (IUD), and do not consent to adequate contraception while on, and for 90 days after the administration of the drug\u002Fplacebo\n18. Currently enrolled in, or has participated in, a clinical trial involving an investigational medicinal product within the past three months (if patients who have participated in a clinical trial involving an investigation medication product are included, they will only be included if they are beyond 5 half-lives from the last dose, and if there is a relevant assay available, there will be undetectable drug levels).\n19. Ongoing substance use which in the opinion of the investigator may affect their participation or compliance with the study protocol\n20. Alcohol consumption more than 7 drinks per week for females and more than 14 drinks per week for males.\n21. Family or personal history of long QT syndrome (\\> 500 msec)\n22. Currently using strong (e.g., fluvoxamine, enoxacin) or moderate (e.g., ciprofloxacin) CYP1A2 Inhibitors. If the patient is able to consult with their prescriber and switch to an alternative medication that is not a CYP1A2 inhibitor, they may be eligible for inclusion in the clinical trial. Any patient who stops a CYP1A2 inhibitor to be enrolled in the clinical trial, we will wait for 7 days or 5 half-lives (whichever is longer) before the study drug is started.\n23. Patients taking strong CYP1A2 inducers, namely Albendazole, Carbamazepine, Primidone and Rifampin, and who cannot stop these drugs safely, will be excluded. If patients could stop these medications, they could be recruited into the study, either 14-days or 5-half lives (whichever is longer) after stopping the study drug.\n24. Glomerular Filtration Rate \\\u003C 60\n25. Life expectancy of less than 2 years in the opinion of the investigator\n26. Any medical condition that, in the opinion of the investigator, might be significantly exacerbated by the known side effects associated with the administration of pirfenidone.\n\nAll participants of childbearing potential, except if post-menopausal \\[see definition of menopause below\\] or had a hysterectomy, bilateral tubal ligation\u002Fclip (surgical sterilization) or surgical removal of both the ovaries), must have a negative urine pregnancy test documented within 2 days prior to initiation of the study drug.\n\nMenopause can be assumed to have occurred when there is either:\n\nA) Either twelve \\[12\\] months of spontaneous amenorrhea; or B) six \\[6\\] months of spontaneous amenorrhea with serum FSH levels \\> 40 mIU\u002FmL; or C) six \\[6\\] weeks postsurgical bilateral oophorectomy with or without hysterectomy.\n\nHormonal deficiency will be documented in the case of suspected spontaneous menopause as follows:\n\n1. If age \\>54 years and with the absence of normal menses: Serum FSH (Follicle Stimulating Hormone) level elevated to within the post-menopausal range based on the laboratory reference range where the hormonal assay is performed;\n2. If age \\\u003C54 years and with the absence of normal menses: Negative serum or urine -Human Chorionic Gonadotropin (HCG) with concurrently elevated serum FSH (Follicle Stimulating Hormone) level in the post-menopausal range, depressed estradiol (E2) level in the post-menopausal range, and absent serum progesterone level, based on the laboratory reference ranges where the hormonal assays are performed","85 Years",{"count":82,"type":21},60,"INTERVENTIONAL",[85],"PHASE2","The proposed project is focused towards evaluation of Pirfenidone as a novel therapeutic strategy in patients with chronic pancreatitis (CP).",[25],[25,89],"Pancreatitis","2026-08-04",{"date":92,"type":35},"2026-08-10",{"date":94,"type":21},"2026-08",{"date":96,"type":21},"2030-08",{"name":98,"class":42},"Vikas Dudeja",{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":83,"phases":109,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":43},"100543923","vr-pilot-for-pancreatitis-100543923","NCT06362187","VR Pilot for Pancreatitis","A Feasibility Study on Gut-Directed Virtual Reality for Chronic Pain Related to Chronic Pancreatitis","Inclusion Criteria:\n\n* Diagnosis of CP \\[as determined by Cambridge 3-4 imaging classification (using CT, MRI, or MRCP) or a histologic diagnosis of CP\\]\n* Clinically significant abdominal pain, measured using the standardized NIH PROMIS GI Pain Scale14 and defined as scoring at least 5 points above the nationally normed score (0.5 SD effect size), indicating equal or greater than the minimally clinically important difference (MCID) of abdominal pain\n* Are 18-75 years of age\n* Are able to read\u002Fwrite English. The study does not include non-English speakers as to current study material are only available in English.\n\nExclusion Criteria:\n\n* Patients who are presenting with a condition that interferes with VR usage (e.g., seizures, facial injury precluding safe placement of headset, visual impairment)\n* Patients who have cognitive impairment that affects protocol participation\n* Patients who are recommended for long-term hospitalization\n* Patients who are estimated to live \\\u003C3 months from the time of enrollment\n* Patients who have been diagnosed with a pancreatic tumor\n* Patients who have been enrolled in an interventional\u002Ftherapeutic drug trial for chronic or recurrent pancreatitis within the last 6 months","75 Years",{"count":108,"type":21},20,[110],"NA","The purpose of the research is to test the feasibility and preliminary impact of a home-based, standardized, gut-directed, virtual reality cognitive behavioral therapy (VR CBT) on clinical and functional outcomes of patients with chronic pancreatitis (CP) pain. The primary research procedures are questionnaires and biometric Fitbit data. The study will enroll adult patients with CP.",[25,113],"Recurrent Pancreatitis","2026-08-03",{"date":116,"type":35},"2026-08-05",{"date":118,"type":21},"2027-07-22",{"date":120,"type":21},"2029-05",{"name":122,"class":42},"Cedars-Sinai Medical Center",{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":130,"targetDuration":4,"studyType":83,"phases":132,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":144},"100498547","early-phase-1-simvastatin-treatment-to-improve-patient-reported-outcomes-in-patients-with-chronic-pancreatitis-100498547","NCT05771675","Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis","SMV in CP","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, aged 18-75 at time of enrollment\n4. Diagnosis of Recurrent Acute or Chronic Pancreatitis not attributable to gallstones (i.e., suspected or definite biliary etiology), medications, trauma or autoimmune pancreatitis. For CP, imaging studies that can be used for diagnosis classification using Cambridge criteria46,47.\n5. Ability to take oral medication and be willing to adhere to the dosing regimen.\n6. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional one month after administration of study medication.\n7. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional one month after administration of study medication.\n8. No prior pancreatic surgery\n9. No current statin use for 6 months.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation\n2. History of autoimmune, medication caused or traumatic pancreatitis.\n3. Primary pancreatic tumors - pancreatic ductal adenocarcinoma, suspected cystic neoplasm (\\>1 cm. in size or main duct involvement), neuroendocrine tumors, and other uncommon tumors.\n4. Pancreatic metastasis from other malignancies.\n5. History of solid organ transplant, HIV\u002FAIDS.\n6. Known isolated pancreatic exocrine insufficiency (i.e.., in the absence of any eligible inclusion criteria).\n7. Subjects required to take itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine, danazol, amiodarone, or verapamil for other clinical indications.\n8. Current simvastatin use within the past 6 months.\n9. Participants must not have medical or psychiatric illnesses or ongoing substance abuse that in the investigator's opinion would compromise their ability to tolerate study interventions or participate in longitudinal follow up.\n10. Patients with active liver disease.\n11. Known Pregnancy. All participants of childbearing potential, except if post-menopausal (i.e., no menses for ≥2 years) or had a hysterectomy, bilateral tubal ligation\u002Fclip (surgical sterilization) or surgical removal of both the ovaries), must have a negative urine or serum B-HCG pregnancy test documented within 2 days prior to any endoscopic or radiologic procedures done for research purposes. Any standard of care tests will follow institutional policies regarding pregnancy test.\n12. Currently incarcerated.\n13. Inability to comply with study activities.",{"count":131,"type":21},90,[133],"EARLY_PHASE1","The purpose of this pilot study to examine the feasibility and acceptability of simvastatin in adults with Recurrent Acute Pancreatitis (RAP) and Chronic Pancreatitis (CP).",[136,25],"Recurrent Acute Pancreatitis","RECRUITING",{"date":116,"type":35},{"date":140,"type":35},"2024-10-24",{"date":142,"type":21},"2028-06",{"name":122,"class":42},5,{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":83,"phases":155,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":43},"100545770","internet-delivered-pain-self-management-for-persons-with-acute-recurrent-and-chronic-pancreatitis-pain-100545770","NCT06386224","Internet-Delivered Pain Self-Management for Persons With Acute Recurrent and Chronic Pancreatitis Pain","Internet-Delivered Pain Self-Management to Reduce Pain and Interference in Chronic Pancreatitis","IMPACT-2","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Willingness to use personal device with internet access (smart phone, computer, iPad) or to borrow a study iPad\u002Fhotspot\n* Diagnosis of CP defined as having obvious morphological features of CP (i.e., Cambridge 3-4 stage or the presence of pancreatic calcifications on CT scan and\u002For magnetic resonance cholangiopancreatography)\n* Diagnosis of RAP defined as having abdominal pain of a duration of \\>=3 months, one episode of acute pancreatitis (AP), or RAP.\n* Having experienced moderate pain intensity (rated as 4 or higher on a 0-10 Numerical Rating Scale) in the last month from RAP or CP.\n\nExclusion Criteria:\n\n* Undergoing treatment for cancer\n* Unable to read English well enough to complete questionnaires or read the study website\n* Currently experiencing suicidal ideation\n* Having received endoscopic therapy in the past 30 days\n* Currently receiving treatment from a psychologist (\\> 4 sessions)",{"count":154,"type":21},280,[110],"Severe and disabling abdominal pain is common in individuals with chronic pancreatitis. Although pain is associated with reduced quality of life and high economic and societal costs, there are limited effective options for pain management in this population. This study proposes an evidence-based psychological intervention approach using an internet-delivered pain self-management program to minimize the impact of pain and improve quality of life. The ultimate goal is to maximize the public health impact of the intervention with successful implementation and dissemination to pancreas clinics and to the community.",[89,25,158],"Acute Recurrent Pancreatitis",[89,160,161,162,163],"Pain","Internet Intervention","Behavioral Intervention","Cognitive Behavioral Therapy","2026-07-15",{"date":166,"type":35},"2026-07-17",{"date":168,"type":35},"2024-05-01",{"date":170,"type":21},"2028-07-01",{"name":172,"class":42},"Seattle Children's Hospital",{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":43},"100647355","neural-sensitisation-and-neuropsychological-alterations-in-painful-chronic-pancreatitis-100647355","NCT07707609","Neural Sensitisation and Neuropsychological Alterations in Painful Chronic Pancreatitis","EVALUATION OF THE RELATIONSHIP BETWEEN NEURAL SENSITISATION AND NEUROPSYCHOLOGICAL ALTERATIONS IN PATIENTS WITH PAINFUL CHRONIC PANCREATITIS","NEURO-CP","Inclusion Criteria:\n\n* Diagnosed with CP confirmed by CECT, MRCP, or EUS based on Cambridge or Rosemont criteria.\n* Age 18-60 years.\n* Both genders\n\nExclusion Criteria:\n\n* Recent episode of acute pancreatitis or ongoing pain (VAS \\>5).\n* Pancreatic cancer and other significant comorbidities.\n* Recent use of antidepressants, anxiolytics, high-potency opioids, or neuromodulators.\n* Pregnancy and lactation.\n* Inability to give informed consent.","60 Years",{"count":183,"type":21},200,"Chronic pancreatitis (CP) is a progressive inflammatory disease in which chronic abdominal pain affects up to 80% of patients and remains difficult to manage despite treatment of pancreatic pathology. Increasing evidence suggests that persistent pain is not solely driven by peripheral pancreatic abnormalities but also by central sensitization, involving maladaptive changes in central nervous system pain-processing pathways. While altered brain connectivity and neurochemical changes have been demonstrated in other chronic pain disorders, these mechanisms remain poorly characterized in CP.\n\nThis study aims to integrate clinical phenotyping with blood-based metabolite profiling and advanced neuroimaging, including resting-state functional MRI and magnetic resonance spectroscopy, to investigate the relationship between central sensitization, brain dysfunction, and neuropsychological alterations. The findings may identify objective neurobiological markers of pain and facilitate the development of mechanism-based, personalized treatment strategies for patients with chronic pancreatitis.",[25,186],"Pain Management",[188,160,189,190,191,25],"Central Sensitisation","Neuroimaging","fMRI","MRS","2026-07-13",{"date":194,"type":35},"2026-07-16",{"date":196,"type":35},"2026-01-06",{"date":198,"type":21},"2026-11-30",{"name":200,"class":42},"Asian Institute of Gastroenterology, India",{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":208,"targetDuration":210,"studyType":22,"phases":4,"briefSummary":211,"conditions":212,"keywords":217,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":43},"100646070","eus-procedures-using-rivos-eus-access-device-100646070","NCT07696572","EUS Procedures Using RIVOS™ EUS Access Device","Registry of Patients Undergoing Endoscopic Ultrasound (EUS) Procedures Using the RIVOS™ EUS Access Device","Inclusion Criteria:\n\n* Age ≥ 18 years\n* All patients undergoing EUS-guided interventions using the RIVOS™ EUS access device\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Patients who did not undergo EUS-guided interventions using the RIVOS™ EUS access device",{"count":209,"type":21},30,"4 Weeks","This is a prospective study of patients undergoing EUS procedures using the RIVOS™ EUS access device.",[213,214,215,25,216],"Pancreatic Fluid Collections","Biliary Obstruction","Pancreatic Duct Obstruction","Pancreatic Cancer Non-resectable",[218,219,220],"EUS-guided bile duct drainage","EUS-guided pancreatogastrostomy","Endoscopic ultrasound","2026-07-06",{"date":223,"type":35},"2026-07-10",{"date":225,"type":21},"2026-07",{"date":227,"type":21},"2027-12",{"name":229,"class":42},"Orlando Health, Inc.",{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":83,"phases":240,"briefSummary":242,"conditions":243,"keywords":245,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":43},"100614920","phase-4-a-study-of-effect-of-secretin-for-in-injection-chirostim-on-pancreatic-fluid-composition-in-healthy-subjects-100614920","NCT07285863","A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects","An Open-Label Study On The Effects Of Human Secretin For Injection (CHIROSTIM) On Pancreatic Fluid Composition In Normal Human Volunteer Participants","Inclusion Criteria\n\n* Males or non-pregnant females\n* Age 18-80.\n* Participants must be in good health based on medical history (ASA Class 3 or below)\n* Participants must be willing and able to provide informed consent\n* Receiving an endoscopic ultrasound for a non-pancreatic indication\n\nExclusion Criteria\n\n* History of any form of pancreatitis and\u002For other pancreatic diseases (e.g. pancreatic cysts, pancreatic masses).\n* History of inflammatory bowel disease\n* History of vagotomy.\n* History of surgically altered upper gastrointestinal anatomy (e.g. gastric bypass, Billroth I\u002FII)\n* History of liver disease\n* Pregnant women or nursing mothers\n* Regular use of anticholinergics\n* \\> 2 drinks of alcohol daily\n* Smokers (cigarette)","80 Years",{"count":239,"type":21},24,[241],"PHASE4","The purpose of this study is to collect pancreas fluid from the duodenum using the endoscopic pancreas function collection method in healthy participants after pancreatic stimulation with human secretin.",[244,25],"Exocrine Pancreatic Insufficiency",[246,247],"pancreatic function test","Pancreatic fluid composition","2026-07-03",{"date":250,"type":35},"2026-07-07",{"date":252,"type":35},"2026-03-11",{"date":254,"type":21},"2028-03",{"name":256,"class":42},"Mayo Clinic",{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":17,"minAge":264,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":268,"conditions":269,"keywords":273,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":4},"100644615","exocrine-endocrine-pancreatic-crosstalk-precision-pathways-to-reframe-diabetes-pathophysiology-100644615","NCT07670871","Exocrine-Endocrine Pancreatic Crosstalk: Precision Pathways to Reframe Diabetes Pathophysiology","EXPAND","Inclusion Criteria:\n\n* Adults aged 20 to 78 years.\n* Ability and willingness to provide written informed consent.\n* Eligibility for one of the study cohorts:\n* Individuals undergoing pancreatectomy for non-endocrine pancreatic disease.\n* Individuals with pancreatic ductal adenocarcinoma undergoing pancreatectomy.\n* Individuals with chronic pancreatitis or a previous episode of acute pancreatitis.\n* Individuals at increased risk of type 2 diabetes mellitus, including impaired fasting glucose and\u002For impaired glucose tolerance.\n* Individuals with newly diagnosed type 2 diabetes mellitus.\n* Ability to undergo study-related metabolic assessments and sample collection procedures.\n\nExclusion Criteria:\n\n* Age \\\u003C20 years or \\>78 years.\n* Inability or unwillingness to provide informed consent.\n* Pregnancy or breastfeeding.\n* Diagnosis of type 1 diabetes mellitus.\n* Participation in another interventional clinical trial involving an investigational medicinal product within 30 days before enrollment.\n* Clinical conditions that preclude completion of the planned metabolic assessments.\n* Inability to comply with study procedures.","20 Years","78 Years",{"count":267,"type":21},440,"The EXPAND study is a prospective observational study designed to investigate the biological mechanisms underlying the heterogeneity of type 2 diabetes and related metabolic disorders.\n\nThe study will enroll adults with and without pancreatic disease, including patients undergoing pancreatic surgery, individuals with chronic pancreatitis, subjects at high risk of type 2 diabetes, and patients with newly diagnosed type 2 diabetes. Clinical, metabolic, imaging, genetic, microbiome, and molecular data will be integrated to identify distinct metabolic endotypes and to investigate the interactions between the exocrine pancreas, endocrine pancreas, and adipose tissue. The ultimate goal is to improve the understanding of diabetes pathophysiology and support the development of precision medicine approaches.",[270,25,271,272],"Type 2 Diabetes Mellitus (T2DM)","Prediabetes","Pancreatic Neoplasms",[274,275,276,277,278,279,280,281,282,283,284,285,286,287],"Metabolic Endotypes","Beta Cell Function","Insulin Secretion","Insulin Sensitivity","Exocrine Pancreas","Endocrine Pancreas","Pancreatic Crosstalk","Precision Medicine","Glucose Metabolism","Oral Glucose Tolerance Test","Genetic Risk Score","Fat Adipose Tissue","Hyperglycemic Clamp","Microbiome","2026-06-22",{"date":290,"type":35},"2026-06-26",{"date":292,"type":21},"2026-09",{"date":294,"type":21},"2031-09",{"name":296,"class":42},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":305,"targetDuration":307,"studyType":22,"phases":4,"briefSummary":308,"conditions":309,"keywords":313,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":325},"100638245","venous-resection-in-patients-undergoing-pancreatic-surgery-100638245","NCT07621029","Venous Resection in Patients Undergoing Pancreatic Surgery","Perioperative Factors Linked to Increased Risk for Thrombosis During Pancreatectomy With Venous Resection: the Influence of Technical Factors and Perioperative Antithrombotic Prophylaxis.","VENUS","Inclusion Criteria:\n\n* Patients undergoing curative pancreatic resection with simultaneous PV\u002FSMV resection; Any final pathology; Date of pancreatic surgery June 1st, 2026 - June 30th, 2027 (prospectively)\n\nExclusion Criteria:\n\n* Distant metastases (M1); Age \\\u003C18 years; R2 resection",{"count":306,"type":21},1000,"6 Months","Pancreatic surgery is the only treatment in the multimodality approach to pancreatic cancer sine qua non long-term survival cannot be achieved. Pancreatectomy with vein resection (PVR) of the portal vein and the superior mesenteric vein (PV\u002FSMV) to address tumors with venous infiltration has become standard of care in pancreatic surgery for the past 20 years. Larger series and meta-analyses show that long-term survival beyond the 5-year threshold can be achieved with PVR, but with somewhat inferior survivor compared to standard pancreatic resections without venous resection. That is most likely due to the fact that tumors necessitating PVR are generally larger, less differentiated, and more likely to express unfavourable features such as perineural infiltration.\n\nRecent publications point out that PVR can be performed in pancreatic centers around the world with comparable morbidity and mortality, irrespective of the countries' income status. Also, benchmark outcomes for PVR in low-risk patients have been established, defining that the accepted risk for venous thrombosis should be lower than 14% at discharge. Despite that, a questionnaire among expert surgeons reveals that even if PVR is considered a standard procedure, surgeons are still concerned about significant morbidity. Also, the perception as to what proportion of patients require venous resection, how it should be performed and what anti-thrombotic prophylaxis should be given varies widely. The reported morbidity and thrombosis rates after different types of venous resections and reconstructions vary from under 2 to over 25%. There is no consensus as to which type of venous reconstruction is associated with most favourable short- and long-term outcomes, what specific surgical manoeuvres and graft materials decrease the overall complication and the vein-resection specific complications rates and what anti-thrombotic prophylaxis is safest (associated with lowest thrombosis rates and bleeding complications). Although some studies suggest that grafts are associated with higher thrombosis rates, there is no profound investigation as to how to avoid the use of grafts or, if necessary, what grafts are associated with least thrombotic risks while not causing increased patient morbidity.\n\nThe purpose of this study is to evaluate different technical manoeuvres, anti-thrombotic prophylaxis strategies and organisational features in a large cohort of patients undergoing PVR in median and large-volume centers in order to assess which factors contribute to vein resection-related specific morbidity.\n\nThe study design is an international multi-center observational cohort study, with retrospective and prospective part, including patients who underwent pancreatic surgery with PV\u002FSMV resection from 2018 to June 30 th 2025 and prospectively 18 months ahead. Perioperative factors, related to technical decisions, perioperative resuscitation, institutional organisational specificities, and anti-thrombotic prophylaxis, associated with increased risk for early (30-day), intermediate 30 days-6 months and late venous thrombosis (\\>6months) will be analysed. The thrombosis rate among the four types of venous reconstructions will be compared while adjusting for the length of the resected vein segment. Median and high-volume pancreatic centers (\\>20 pancreatic resected \u002Fyear).\n\nThe inclusion criteria are: patients undergoing radical pancreatic resection with simultaneous PV\u002FSMV resection, irrespective of final pathology operated between January 1 st 2018 - June 30 th, 2025 (retrospectively) or from July 1 st 2025-December 30 th, 2026 (prospectively). Patients with distant metastases (M1), \\\u003C18 years of age or undergoing R2 resection will be excluded.\n\nThe study intends to include over 1000 patients. The main objective is to assess the perioperative factors (technical, organisational, anti-thrombotic treatment) associated with increased risk for early (30 days), intermediate (\\>30 days-6 months) and late (\\>6 months) venous thrombosis.",[310,311,312,25],"IPMN, Pancreatic","Pancreatic Cancer, Resected","Pancreatic Cancer Borderline",[314,315],"Pancreatic surgery","Venous resection","2026-05-27",{"date":318,"type":35},"2026-06-02",{"date":320,"type":21},"2026-06-01",{"date":322,"type":21},"2027-12-31",{"name":324,"class":42},"Sahlgrenska University Hospital",2,{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":17,"minAge":332,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":336,"conditions":337,"keywords":339,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":349},"100321125","evaluation-of-a-mixed-meal-test-for-diagnosis-and-characterization-and-type-3c-diabetes-mellitus-secondary-to-pancreatic-cancer-and-chronic-pancreatitis-detect-100321125","NCT03460769","Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)","Inclusion Criteria:\n\n* All Participants must sign an informed consent indicating that they are aware of the investigational nature of this study. Participants must have signed an authorization for the release of their protected health information.\n* Participants must be ages ≥30 and \\\u003C85.\n* Participants must have a diagnosis of one of the following based on study definitions;\n* New Onset Diabetes (\\\u003C3 years) in participants with Pancreatic Cancer (PDAC);\n* New Onset Diabetes (\\\u003C3 years) in participants with Chronic Pancreatitis;\n* New Onset Diabetes (\\\u003C3 years) in participants without Pancreatic disease (i.e., T2DM)\n* Long standing T2DM (≥3 years) without Pancreatic disease\n* Long standing diabetes (≥3 years) in participants with PDAC\n* Long standing diabetes (≥3 years) participants with chronic pancreatitis\n* non-diabetic participants with PDAC\n* non-diabetic participants with chronic pancreatitis\n* non-diabetic controls without Pancreatic disease\n\nExclusion Criteria:\n\n* Participants must not have any significant medical illnesses (including diabetes) that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the Participant's ability to tolerate study interventions.\n* Diabetes not stable enough to permit holding of diabetes medications in Participants undergoing mixed meal tolerance testing.\n* Participants taking higher doses of insulin (≥0.75 unit\u002Fkg\u002Fday). \\[Criterion is not applicable for PDAC Participants undergoing fasting only blood collection\\]\n* Participants in the non-pancreatic disease subgroup on longer acting agents, including thiazolidinediones and once-weekly GLP-1 agonists (Bydureon \\[exenatide\\], Ozempic \\[semaglutide\\], Trulicity \\[dulaglutide\\]). \\[Criterion is not applicable for Participants in the CP and PDAC groups\\].\n* Participants currently receiving oral steroid medications.\n* Hospitalization for acute pancreatitis within 2 months before study visit. \\[Criterion is not applicable for PDAC Participants undergoing fasting only blood collection\\]\n* The presence of a symptomatic cyst in Participants with CP. \\[Criterion is not applicable for PDAC Participants undergoing fasting only blood collection; this includes cancer arising from a mucinous cystic lesion\\].\n* Any Participant with a known pancreatic cancer histologic subtype other than adenocarcinoma (e.g., Participants with pancreatic neuroendocrine tumors are excluded).\n* Previous pancreatic surgery (including total pancreatectomy, pancreaticoduodenectomy, distal pancreatectomy, pancreaticojejunostomy, enucleation, or Frey procedure). \\[Criterion is not applicable for CP Participants with diabetes who have a history of pancreaticoduodenectomy, pancreaticojejunostomy, distal pancreatectomy, or Frey\\].\n* Previous treatment for pancreatic cancer, including chemotherapy or radiation.\n* Previous vagotomy or gastric surgery, including endoscopic gastric reduction procedures. \\[Criterion is not applicable for PDAC Participants undergoing fasting only blood collection\\].\n* Previous diagnosis of gastroparesis. \\[Criterion is not applicable for PDAC Participants undergoing fasting only blood collection\\].\n* Participants on treatment for any cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix).\n* Allergy or intolerance to ingredients in Boost drink in Participants undergoing mixed meal testing (see Appendix 13.9) \\[Criterion is not applicable for PDAC Participants undergoing fasting only blood collection\\].","30 Years","84 Years",{"count":335,"type":21},775,"The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). Similar to all studies that will be coordinated and managed by the CDMC, no patient enrollment will occur at MDACC. All patient recruitment will occur at external sites that are a part of the CPDPC, which are listed in the appended DETECT protocol. The data management systems, auditing, and monitoring effort are supported by the CDMC.",[57,25,338],"Diabetes Mellitus Type 3c",[57,25,338,340],"Data management",{"date":342,"type":35},"2026-05-29",{"date":344,"type":35},"2021-04-01",{"date":346,"type":21},"2027-06-30",{"name":348,"class":42},"M.D. Anderson Cancer Center",10,{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":356,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":360,"conditions":361,"keywords":364,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":325},"100634219","validation-of-the-odesa-criteria-2026-for-autoimmune-pancreatitis-100634219","NCT07536841","Validation of the Odesa Criteria 2026 for Autoimmune Pancreatitis","Validation of the Odesa Criteria 2026 (OC26) for the Diagnosis of Autoimmune Pancreatitis","ОС26","Inclusion Criteria:\n\n* Adults (≥18 years) undergoing evaluation for suspected autoimmune pancreatitis.\n* Availability of clinical, serological, imaging, and\u002For histological data required for OC26 scoring.\n* Ability to provide informed consent (for prospective participants).\n\nExclusion Criteria:\n\n* Confirmed alternative diagnosis explaining pancreatic findings (e.g., pancreatic cancer, acute pancreatitis of other etiology).\n* Incomplete diagnostic data preventing OC26 scoring.\n* Prior pancreatic surgery altering diagnostic interpretation.",{"count":359,"type":21},82,"This ambispective observational study aims to validate the Odesa Criteria 2026 (OC26), a flexible domain-based point scoring system for diagnosing autoimmune pancreatitis. The study evaluates diagnostic accuracy and reproducibility of OC26 across clinical, serological, morphological, and histological domains.",[362,363,57,25],"Autoimmune Pancreatitis","IgG4-Related Diseases",[365,366,367,368,220,369,370,371,372],"AIP","IgG4","Autoimmune pancreatitis diagnosis","Pancreatic imaging","Serum protein fractions","IgG6\u002FIgG8 ratio","Odesa Criteria 2026 (OC26)","EUS Doppler","2026-05-23",{"date":375,"type":35},"2026-05-28",{"date":377,"type":35},"2026-05-01",{"date":379,"type":21},"2026-12-01",{"name":381,"class":42},"Military Medical Clinical Center of the Southern Region, Ukraine",{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":387,"targetDuration":388,"studyType":22,"phases":4,"briefSummary":389,"conditions":390,"keywords":391,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":398,"completionDateStruct":399,"leadSponsor":400,"locationsCount":4},"100639693","immune-repertoire-decoding-for-chronic-pancreatitis-to-pancreatic-cancer-risk-stratification-100639693","NCT07612566","Immune Repertoire Decoding for Chronic Pancreatitis-to-Pancreatic Cancer Risk Stratification",{"count":53,"type":21},"30 Months","This study will follow people with chronic pancreatitis, people with pancreatic cancer, and healthy volunteers. The goal is to better understand why some people with chronic pancreatitis may later develop pancreatic cancer.\n\nParticipants will provide blood samples and health information. Some participants may also provide tissue samples if these are available during routine medical care. The study team will look for changes in the immune system, genes, medical images, and clinical information that may be linked to the development of pancreatic cancer.\n\nPeople with chronic pancreatitis will be followed over time. The information collected in this study may help researchers develop a model to identify patients with chronic pancreatitis who have a higher risk of pancreatic cancer.",[25,57],[59,392,393,394,63,395],"Immune Repertoire","T-Cell Receptor","B-Cell Receptor","Artificial Intelligence","2026-05-21",{"date":375,"type":35},{"date":320,"type":21},{"date":69,"type":21},{"name":71,"class":42},{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":409,"targetDuration":4,"studyType":83,"phases":411,"briefSummary":412,"conditions":413,"keywords":414,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":421,"startDateStruct":422,"completionDateStruct":423,"leadSponsor":425,"locationsCount":43},"100635958","palatable-elemental-diet-for-gastrointestinal-symptoms-in-chronic-pancreatitis-100635958","NCT07559448","Palatable Elemental Diet for Gastrointestinal Symptoms in Chronic Pancreatitis","Feasibility of a Novel Oral Palatable Elemental Diet for Gastrointestinal Symptoms in Chronic Pancreatitis","PEACE-CP","Inclusion Criteria:\n\n* Adults aged 18 to 75 years\n* Clinical diagnosis of chronic pancreatitis based on medical history and study physician assessment\n* Self-reported chronic pancreatitis-related gastrointestinal symptoms within 30 days before enrollment, with significant global gastrointestinal symptom burden defined as a Structured Assessment of Gastrointestinal Symptoms (SAGIS) score of 16 or higher\n\nExclusion Criteria:\n\n* Pancreatic tumor or pancreatic cancer\n* History of pancreatic surgery\n* Pregnancy or breastfeeding\n* Diagnosis of a condition other than chronic pancreatitis that contributes to gastrointestinal symptoms, based on medical history or study physician assessment\n* Active infection or antibiotic use within the last month\n* History of phenylketonuria\n* Insulin-dependent diabetes or diabetes requiring insulin treatment",{"count":410,"type":21},15,[110],"The goal of this clinical trial is to learn whether a 2-week exclusive palatable elemental diet is feasible, tolerable, and acceptable for adults with chronic pancreatitis and bothersome gastrointestinal symptoms. An elemental diet is a nutritionally complete formula made from ingredients that are easy to absorb. The main questions it aims to answer are whether participants can complete the diet as planned, and whether they can take in most of the prescribed formula, and how acceptable the study diet is to participants at the end of the 2-week diet period.",[25],[27,415,416,417,418,419,420],"elemental diet","palatable elemental diet","gastrointestinal symptoms","abdominal pain","microbiome","feasibility study",{"date":316,"type":35},{"date":94,"type":21},{"date":424,"type":21},"2028-08",{"name":426,"class":42},"Stanford University",{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":83,"phases":436,"briefSummary":437,"conditions":438,"keywords":439,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":325},"100625127","phase-4-malabsorption-blood-test-mbt-to-determine-exocrine-pancreatic-function-and-related-quality-of-life-in-chronic-pancreatitis-100625127","NCT07418593","Malabsorption Blood Test (MBT) to Determine Exocrine Pancreatic Function and Related Quality of Life in Chronic Pancreatitis","MBT","Inclusion Criteria\n\n* ≥ 18 years of age\n* RAP (≥ 2 documented lifetime attacks with ≥ 2 of 3 acute pancreatitis criteria) OR Chronic pancreatitis (Cambridge I or II with documented history of AP OR Cambridge III or IV criteria)\n* Fecal elastase ≥ 50 within the preceding 12 months\n\nExclusion Criteria\n\n* Allergy\u002FIntolerance to PERT\u002FMBT\n* Taking medications that alter fat absorption or that supplement the fatty acids being studied (e.g. orlistat, ursodeoxycholic acid, Fatty-15 fatty acid supplement etc.)\n* Taking GLP-1 Receptor Agonist therapy\n* Fecal elastase \\\u003C50 within preceding 12 months OR pre-existing diagnosis of severe Exocrine Pancreatic Insufficiency, or ongoing steatorrhea\n* Receiving Pancreatic Enzyme Replacement Therapy for \\> 5 days within the preceding 30 days\n* Acute Pancreatitis attack (documented and meeting at least 2 of 3 criteria) within the preceding 90 days\n* History of pancreatic resection or underlying malabsorptive disease\n* Pregnant or Breast Feeding\n* Other significant medical condition as judged by Principal Investigator",{"count":435,"type":21},80,[241],"This project uses the Malabsorption Blood Test (MBT) to identify patients with recurrent acute or chronic pancreatitis who have mild to moderate exocrine pancreatic insufficiency. A subgroup of patients who have response to pancreatic enzyme replacement therapy will enter a randomized, placebo-controlled pilot clinical trial for 8 weeks to identify improvements in quality of life (QOL).",[25,136,244],[440,441,442,244],"Malabsorption Blood Test(MBT)","Chronic pancreatitis","Recurrent Acute pancreatitis","2026-04-21",{"date":445,"type":35},"2026-04-27",{"date":447,"type":35},"2026-04-20",{"date":449,"type":21},"2028-09",{"name":451,"class":42},"Anna Evans Phillips",{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":460,"targetDuration":4,"studyType":83,"phases":462,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":43},"100531864","early-phase-1-safety-and-efficacy-of-mesenchymal-stem-cells-associated-with-chronic-pancreatitis-pain-100531864","NCT06205342","Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain","STEMCAP-1: Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain","STEMCAP-1","Inclusion Criteria:\n\n1. Age between 18 and 75 years old, male or female\n2. Definite chronic pancreatitis\n3. Patients who are diagnosed with painful CP for more than 6 months may be constant or may have been waxing and waning\u002Fremitting.\n4. Baseline Izbicki pain score \\> 30\n5. Stable dose of opioids for the past 30 days\n\nExclusion Criteria:\n\n1. Acute pancreatitis per 2012 revised Atlanta criteria within the last 30 days.\n\n   * The revised Atlanta classification requires that two or more of the following criteria be met for the diagnosis of acute pancreatitis: (a) abdominal pain suggestive of pancreatitis, (b) serum amylase or lipase level greater than three times the upper normal value, or (c) characteristic imaging findings.\n2. Chronic pain syndromes other than pancreatitis that require daily use of opioids in the past 30 days.\n3. Severe organ failure(s) likely to interfere with clinical pain outcomes within 6 months.\n4. HbA1c \\>10%\n5. Laboratory values of WBC \\\u003C2.0 cells\u002F10\\^3, Hemoglobin \\\u003C8 gm\u002Fdl, and platelets \\\u003C100K cells\u002F10\\^3, AST or ALT \\> 3 times the upper limit of normal, or creatinine \\>2.0 mg\u002Fdl\n6. New York Heart Association Class 2 or higher congestive heart failure\n7. Current lung, hematologic, or solid organ malignancy other than skin, or cervical stage 1 cancers within the past 3 years.\n8. Subjects with current infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection.\n9. Active malignancy with the exception of non-melanoma skin cancer.\n10. Any subject who has received an investigational drug or device within 30 days before randomization or who is expected to receive an investigational drug or device during this study.\n11. Patients with planned endoscopic or surgical intervention, surgical resection or needle drainage of pancreatic structures in the next 6 months.\n12. Patients who have had a pancreatic surgery, endoscopic procedure with therapy, or hospitalization related to pancreatitis within the last 90 days\n13. Subjects who have had any ongoing alcohol abuse and\u002For any illegal drug abuse within the past 6 months.\n14. Subjects with infected pancreatic pseudocysts or pancreatic walled-off necrotic areas at the time of consent\n15. Females who are pregnant or women of childbearing potential (WOCBP) and males with female partners of childbearing potential who are not willing to use adequate contraception during the study\n16. Breastfeeding females\n17. Subject unwilling to follow the protocol and assessments",{"count":461,"type":21},48,[133],"This protocol aims to test whether an infusion of allogeneic bone marrow-derived mesenchymal stromal cells (BM-MSCs) can reduce pain associated with chronic pancreatitis (CP) and explore potential mechanisms of MSC action.",[25,465],"Chronic Pain","2026-04-14",{"date":468,"type":35},"2026-04-17",{"date":470,"type":35},"2024-07-17",{"date":472,"type":21},"2028-06-01",{"name":474,"class":42},"Medical University of South Carolina",{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":482,"targetDuration":4,"studyType":83,"phases":484,"briefSummary":486,"conditions":487,"keywords":489,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":498,"locationsCount":43},"100446599","phase-1-autologous-mesenchymal-stromal-cells-and-islet-co-transplantation-in-tp-iat-100446599","NCT05095532","Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT","Autologous Mesenchymal Stromal Cells and Islet Co-transplantation to Enhance Islet Survival and Function in Chronic Pancreatitis Patients Undergo Total Pancreatectomy and Islet Autotransplantation","Inclusion Criteria:\n\n* Diagnosis of CP and scheduled for TP-IAT;\n* ≥18 years old;\n* Diabetes with HbA1c \\\u003C12%.\n\nExclusion Criteria:\n\n* Patients who are under immunosuppression;\n* Pregnant and breastfeeding women.\n* Patients who have liver damage based on ALT, AST, and total bilirubin levels (\\>3 times normal levels);",{"count":483,"type":21},42,[485],"PHASE1","This is a clinical trial for chronic pancreatitis (CP) patients undergoing total pancreatectomy with islet autotransplantation (TP-IAT). Participants will be randomized to either bone marrow-derived mesenchymal stem cells (MSCs) or control with the standard of care. Participants will be followed for one-year post-transplant.",[25,488],"Mesenchymal Stem Cells",[490,491],"Total Pancreatectomy","TP-IAT","2026-04-13",{"date":494,"type":35},"2026-04-16",{"date":496,"type":35},"2021-12-01",{"date":346,"type":21},{"name":474,"class":42},{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":506,"targetDuration":508,"studyType":22,"phases":4,"briefSummary":509,"conditions":510,"keywords":515,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":43},"100424911","prospective-registry-of-therapeutic-endoscopic-ultrasound-100424911","NCT04813055","Prospective Registry Of Therapeutic EndoscopiC ulTrasound","PROTECT","Inclusion Criteria:\n\n* subjects candidate to therapeutic EUS (T-EUS) procedures for any underlying disease\n* subject eligible to T-EUS procedures but undergoing other non-EUS based endoscopic procedures, percutaneous or surgical procedures\n* 18 years old or older\n* able to provide an informed consent to inclusion.\n\nExclusion Criteria:\n\n* age \\\u003C 18 years\n* inability or unwillingness to sign the informed consent form (ICF)\n* contra-indication for endoscopy or use of fluoroscopy",{"count":507,"type":21},510,"12 Months","This registry aims to analyze long-term outcomes of therapeutic EUS (T-EUS) procedures, as well as to describe clinical and technical variables potentially predicting clinical success or adverse events, for a better selection of ideal candidates.\n\nThe study also includes standard alternatives to T-EUS procedures for outcomes comparison.",[511,214,512,513,514,25],"Gastric Outlet Obstruction","Acute Pancreatic Fluid Collection","Acute Pancreatitis With Infected Necrosis","Acute Cholecystitis",[220,516,517,518,519,520,521],"Therapeutic EUS","Interventional EUS","Biliary Drainage","Gastro-jejunostomy","Gallbladder Drainage","Endoscopy","2026-04-10",{"date":492,"type":35},{"date":525,"type":35},"2020-12-01",{"date":527,"type":21},"2026-12-31",{"name":529,"class":42},"Paolo Giorgio Arcidiacono, MD",{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":536,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":538,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":540,"conditions":541,"keywords":545,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":43},"100629789","breath-test-based-assessment-of-sibo-in-chronic-pancreatitis-and-partial-pancreatectomy-100629789","NCT07479238","Breath Test-Based Assessment of SIBO in Chronic Pancreatitis and Partial Pancreatectomy","Prevalence of SIBO in Patients With Chronic Pancreatitis and After Partial Pancreatectomy: Assessment by Glucose, Lactulose and Mixed Triglyceride Breath Tests.","DCP-PCT-EPI","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Ability and willingness to participate in the study and to comply with study procedures\n* Diagnosis of chronic pancreatitis with pancreatic exocrine insufficiency (defined as fecal elastase \\\u003C 200 µg\u002Fg of stool)\n* Ongoing pancreatic enzyme replacement therapy (PERT) with persistent gastrointestinal symptoms (including abdominal pain, dyspepsia, bloating, excessive flatulence, diarrhea, or steatorrhea) or unintentional weight loss ≥ 10% within the previous 6 months despite adequate PERT dosing (≥ 40,000 IU per main meal and half dose for snacks)\n* Patients with ampullary or pancreatic tumors who underwent partial pancreatectomy and subsequently developed pancreatic exocrine insufficiency with persistent gastrointestinal symptoms\n* Indication to undergo glucose, lactulose, and mixed triglyceride breath tests as part of routine clinical practice\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years or \\> 75 years\n* Pancreatic adenocarcinoma or bile duct tumors under active or previous adjuvant therapy\n* Moderate to severe liver disease\n* Severe chronic kidney disease (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²)\n* History of major gastrointestinal surgery, including total pancreatectomy\n* Presence of other active organic gastrointestinal diseases\n* Diabetic gastroparesis\n* Known celiac disease\n* Obstructive jaundice\n* Liver cirrhosis Child-Pugh class C\n* Recent or ongoing infections\n* Severe chronic obstructive pulmonary disease (COPD)\n* Symptomatic thyroid disorders\n* Use of antibiotics, laxatives, probiotics, or prokinetic agents within 4 weeks prior to breath testing\n* Inability or refusal to undergo study procedures\n* Inability or refusal to provide informed consent",{"count":539,"type":21},100,"Pancreatic exocrine insufficiency (PEI) results from reduced pancreatic enzyme secretion, leading to malabsorption, malnutrition, and impaired quality of life. Although pancreatic enzyme replacement therapy (PERT) is the standard treatment, some patients remain symptomatic despite apparently adequate therapy. Possible causes include suboptimal dosing or concomitant conditions such as small intestinal bacterial overgrowth (SIBO). This study aims to determine the prevalence of SIBO in symptomatic PEI patients despite adequate PERT and to identify treatable causes of persistent symptoms using non-invasive diagnostic tests, with the goal of improving nutritional status and quality of life.",[542,543,25,544],"SIBO","Pancreatic Insufficiency","Pancreatic Surgey",[546,441,547,548],"Pancreatic exocrine insufficiency","enzyme replacement therapy","Small intestinal bacterial overgrowth","2026-04-09",{"date":492,"type":35},{"date":552,"type":21},"2026-04-30",{"date":554,"type":21},"2028-04-26",{"name":296,"class":42},{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":563,"targetDuration":4,"studyType":83,"phases":565,"briefSummary":566,"conditions":567,"keywords":568,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":579,"locationsCount":43},"100510330","phase-1-novel-cellular-therapy-for-the-treatment-of-pain-associated-with-chronic-pancreatitis-100510330","NCT05925036","Novel Cellular Therapy for the Treatment of Pain Associated With Chronic Pancreatitis","MSCPainRelief","Inclusion Criteria:\n\n* Age between 18 and 75 years old, male or female\n* Definite chronic pancreatitis M-ANNHEIM criteria (Tsimmerman Ia, 2008) One or more of the following are required:\n* Pancreatic calcifications\n* Moderate or marked ductal lesions\n* Marked and persistent exocrine insufficiency defined as pancreatic steatorrhea markedly reduced by enzyme supplementation\n* Typical histology of an adequate histological specimen\n* Patients who are diagnosed with painful CP for more than 6 months may be constant or may have been waxing and waning\u002Fremitting.\n* Baseline Izbicki pain score \\> 30 (Dworkin et al., 2005)\n* Stable dose of opioids for the past 30 days\n\nExclusion Criteria:\n\n* Acute pancreatitis per 2012 revised Atlanta criteria (23) within the last 30 days oThe revised Atlanta classification requires that two or more of the following criteria be met for the diagnosis of acute pancreatitis: (a) abdominal pain suggestive of pancreatitis, (b) serum amylase or lipase level greater than three times the upper normal value, or (c) characteristic imaging findings.\n* Chronic pain syndromes other than pancreatitis that require daily use of opioids in the past 30 days.\n* Hemoglobin of \\\u003C8.0g\u002FdL, EGFR\\\u003C60 ml\u002Fmin, AST or ALT \\>2 times upper limit of normal, Bilirubin \\> 1.5 mg\u002Fdl unless the subject has confirmed Gilbert syndrome., Platelets \\\u003C100,000\u002Fmicroliter, HbA1c \\>10%\n* Congestive Heart Failure NYHA class \\>1\n* History of Malignancy except for in situ malignancies that have been surgically treated and basal cell skin cancers\n* Evidence of active infection using current antibiotics or with Hepatitis B, C, or HIV\n* Known intravenous contrast allergy causing anaphylaxis\n* Any subject who has had an ongoing alcohol abuse and\u002For illegal drug dependencies within the past six months.\n* Any subject who has received an investigational drug or device within 30 days before randomization or who is expected to receive an investigational drug or device during this study.\n* Patients with planned endoscopic or surgical intervention, surgical resection or needle drainage of pancreatic structures in the next 6 months.\n* Subjects with infected pancreatic pseudocysts or pancreatic walled-off necrotic areas at the time of consent\n* Females who are pregnant or women of childbearing potential (WOCBP) and males with female partners of childbearing potential who are not willing to use adequate contraception during the study\n* Breastfeeding females\n* Subject unwilling to follow the protocol and assessment",{"count":564,"type":21},40,[485],"The goal of this clinical trial is to test whether adult stem cells, called mesenchymal stem cells (MSCs) collected from the patient's bone marrow can help reduce pain caused by chronic pancreatitis and improve pancreatic function.",[25,465],[569,441,570,571,572],"Mesenchymal stem cells (MSCs)","Pain relief","Pancreas dysfunction","Fibrosis","2026-04-01",{"date":575,"type":35},"2026-04-07",{"date":577,"type":35},"2024-01-01",{"date":322,"type":21},{"name":580,"class":581},"VA Office of Research and Development","FED",{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":4,"eligibilityCriteria":588,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":589,"targetDuration":591,"studyType":22,"phases":4,"briefSummary":592,"conditions":593,"keywords":600,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":619},"100120158","collecting-medical-information-and-tissue-samples-from-patients-with-pancreatic-cancer-or-other-pancreatic-disorders-100120158","NCT00830557","Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders","Biospecimen Resource for Pancreas Disease, a Data & Tissue Bank (Also Known as a Bio-repository, Bio-bank, Data & Tissue Database, Data & Tissue Registry, Etc.) to Help Advance Research in Pancreas Disease","* Known or suspected pancreas disease including:\n\n  * pancreas adenocarcinoma\n  * islet cell cancer\n  * pancreatic cysts\n  * pancreatitis (hereditary, acute, or chronic)\n* Next of kin of deceased participant who did not complete participation before passing away\n\nExclusion Criteria:\n\n* Under the age of 18\n* Unable to provide informed consent\n* Prison inmates",{"count":590,"type":21},20000,"1 Year","RATIONALE: Gathering medical information and collecting and storing samples of blood and tissue to test in the laboratory may help doctors develop better ways to screen people at risk for pancreatic cancer or other pancreatic disorders in the future.\n\nPURPOSE: This clinical trial is collecting medical information and tissue samples from patients with pancreatic cancer or other pancreatic disorders.",[594,57,595,596,25,597,598,599],"Islet Cell Tumor","Pancreatic Disease","Acute Pancreatitis","Hereditary Pancreatitis","Pancreatic Neuroendocrine Carcinoma","Pancreatic Adenocarcinoma",[601,602,603,604,605,606,607,608,609,610],"recurrent pancreatic cancer","stage I pancreatic cancer","stage II pancreatic cancer","stage III pancreatic cancer","stage IV pancreatic cancer","recurrent islet cell carcinoma","pancreatic alpha cell carcinoma","pancreatic beta islet cell carcinoma","pancreatic delta cell carcinoma","pancreatic G-cell carcinoma","2026-03-05",{"date":613,"type":35},"2026-03-09",{"date":615,"type":35},"2000-10-01",{"date":617,"type":21},"2027-08-30",{"name":256,"class":42},3,{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":4,"eligibilityCriteria":626,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":627,"enrollmentInfo":628,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":630,"conditions":631,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":636,"completionDateStruct":637,"leadSponsor":639,"locationsCount":640},"100566161","biospecimen-collection-to-identify-gene-mutations-for-high-risk-pancreatic-cancer-in-pediatric-patients-insppire-2-study-100566161","NCT06651580","Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study","Pediatric Longitudinal Cohort Study of Chronic Pancreatitis (INSPPIRE 2)","Inclusion Criteria:\n\n* All subjects\u002Fparents must sign an informed consent and\u002For assent indicating that they are aware of the investigational nature of this study\n* Subjects\u002Fparents must have signed an authorization for the release of their or their child's protected health information\n* All children must be under 18 years of age at the time of enrollment\n* All children providing samples should fit the ARP or CP inclusion criteria defined below:\n\n  * Acute pancreatitis (AP): AP is defined as requiring 2 of the following:\n\n    * Abdominal pain compatible with AP\n    * Serum amylase and\u002For lipase values \\>= 3 times upper limits of normal\n    * Imaging findings of AP, such as gland enlargement, acute inflammatory changes, and fluid collections\n  * ARP is defined as: At least 2 episodes of acute pancreatitis with complete resolution of pain and a \\>= 1 month pain-free interval between episodes\n  * Chronic Pancreatitis:\n\n    * Children with at least:\n\n      * One irreversible structural change in the pancreas with or without abdominal pain +\u002F- exocrine pancreatic insufficiency +\u002F- diabetes\n\n        * Irreversible structural changes:\n\n          * Ductal calculi, dilated side branches, parenchymal calcifications found in any imaging (abdominal ultrasound \\[abd US\\], magnetic resonance imaging\u002Fmagnetic resonance cholangiopancreatography \\[MRI\u002FMRCP\\], computerized tomography \\[CT\\], endoscopic retrograde cholangiopancreatography \\[ERCP\\], endoscopic US \\[EUS\\])\n          * Ductal obstruction or stricture\u002Fdilatation\u002Firregularities that are persistent (for \\>= 2 months) on any imaging\n          * Parenchymal atrophy, irregular contour, accentuated lobular architecture, cavities alone are not diagnostic findings for CP\n          * Surgical or pancreatic biopsy specimen demonstrating histopathologic features compatible with CP (acinar atrophy, fibrosis, protein plugs, infiltration with lymphocytes, plasma cells, macrophages)\n\nExclusion Criteria:\n\n* Subjects must not have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the subject's ability to tolerate study interventions","17 Years",{"count":629,"type":21},1600,"This clinical trial collects blood, saliva, urine, or stool samples to help identify possible genetic mutations that may increase a person's chance at developing pancreatic cancer. Finding genetic markers among pediatric patients with acute recurrent pancreatitis and chronic pancreatitis may help identify patients who are at risk of pancreatic cancer.",[25,632,136],"Exocrine Pancreas Carcinoma","2026-03-03",{"date":635,"type":35},"2026-03-04",{"date":344,"type":35},{"date":638,"type":21},"2027-02-02",{"name":348,"class":42},26,{"id":642,"slug":643,"hasResults":12,"nctId":644,"briefTitle":645,"officialTitle":646,"acronym":647,"eligibilityCriteria":648,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":237,"enrollmentInfo":649,"targetDuration":4,"studyType":83,"phases":651,"briefSummary":652,"conditions":653,"keywords":654,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":665,"lastUpdatePostDateStruct":666,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":670,"locationsCount":43},"100627365","phase-1-soy-tomato-juice-to-improve-outcomes-in-pancreatitis-100627365","NCT07447687","Soy Tomato Juice to Improve Outcomes in Pancreatitis","Soy Tomato Juice to Improve Outcomes in Pancreatitis (the STOP Trial): a Phase 1\u002F2 Single Arm Trial","STOP","Inclusion Criteria:\n\n* Diagnosis of definite chronic pancreatitis (CP) or recurrent acute pancreatitis (RAP)\n* Patients should be able to fully understand and participate in all aspects of the study\n\nExclusion Criteria:\n\n* Episode of acute pancreatitis, hospitalization, or endoscopic\u002Fsurgical intervention within 30 days of enrollment\n* Chronic, daily use of systemic immunomodulatory medication for any indication\n* Previous allergic reaction to soy or tomato products\n* Known pregnancy",{"count":650,"type":21},35,[485,85],"This goal of this clinical trial is to see if people with recurrent acute pancreatitis or chronic pancreatitis can tolerate and regularly drink a tomato juice beverage. Researchers will also measure inflammation and ask participants to report how they feel. Everyone in the study will receive the tomato juice drink, and both participants and researchers will know what is being taken. The investigators expect the drink will be well tolerated, may lower inflammation, and may improve participant-reported symptoms and quality of life.",[136,25],[655,656,657,418,658,659,660,661,662,663,664],"Soy","Tomato","Dietary Intervention","inflammation","lycopene","soy isoflavones","anti-inflammatory diet","medical nutrition","diet","Ohio State University","2026-02-26",{"date":633,"type":35},{"date":668,"type":21},"2026-02",{"date":142,"type":21},{"name":664,"class":42},{"id":672,"slug":673,"hasResults":12,"nctId":674,"briefTitle":675,"officialTitle":676,"acronym":4,"eligibilityCriteria":677,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":237,"enrollmentInfo":678,"targetDuration":591,"studyType":22,"phases":4,"briefSummary":680,"conditions":681,"keywords":686,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":688,"lastUpdatePostDateStruct":689,"startDateStruct":691,"completionDateStruct":693,"leadSponsor":695,"locationsCount":43},"100626755","ai-powered-precision-decision-making-for-pancreatic-diseases-100626755","NCT07439757","AI-Powered Precision Decision-Making for Pancreatic Diseases","A Multicenter Clinical Study on AI-Powered Precision Decision-Making Management for Pancreatic Diseases Using Contrast-Enhanced CT","Inclusion Criteria:\n\n* Clinically suspected pancreatic disease.\n* Scheduled to undergo contrast-enhanced CT.\n* Signed informed consent form indicating agreement to participate.\n\nExclusion Criteria:\n\n* History of pancreatic surgery.\n* Contraindications to contrast-enhanced CT, including known hypersensitivity to iodinated contrast media or severe renal\u002Fhepatic dysfunction.\n* Suboptimal image quality affecting diagnosis.\n* Concurrent participation in another interventional clinical trial.\n* Unsuitability for participation as determined by the investigator, including but not limited to: pregnancy or lactation, severe psychiatric disorders or cognitive impairment, significant comorbidities that may interfere with study results or patient safety.",{"count":679,"type":21},2000,"This multicenter clinical trial evaluates an artificial intelligence (AI) system designed to assist in the diagnosis and management of pancreatic diseases. Using contrast-enhanced CT scans, the study compares the AI's recommendations against the decisions of experienced clinicians to verify the system's accuracy and safety in a real-world setting. Patients are categorized into three management groups: Intervention (surgery\u002Ftreatment), Intensive Surveillance (close monitoring), or Routine Surveillance (standard follow-up). The primary goal is to determine if the AI system can reliably classify patients, reduce the risk of missing malignant lesions, and prevent unnecessary surgeries, thereby improving clinical decision-making for pancreatic conditions.",[57,682,310,683,25,684,685],"Diagnose Disease","Pancreatic Cystic Lesions","Pancreatic Neuroendocrine Tumor","Acute Pancreatitis (AP)",[687],"Artificial Intelligence (AI), Deep Learning, Contrast-Enhanced CT, Multicenter Clinical Trial, Real-World Study","2026-02-23",{"date":690,"type":35},"2026-02-27",{"date":692,"type":21},"2026-03-01",{"date":694,"type":21},"2029-10-31",{"name":71,"class":42}]